<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537133</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 003</org_study_id>
    <secondary_id>U10HL098115</secondary_id>
    <nct_id>NCT01537133</nct_id>
  </id_info>
  <brief_title>Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment</brief_title>
  <official_title>Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are new, very sensitive methods for detecting bacteria. These methods show that
      hundreds of millions of microbes (organisms that can only be seen with microscopes),
      especially bacteria, live in healthy people. The collection of different microbes found in a
      site is called a &quot;microbiome.&quot; The investigators know that microbiomes of the skin, sinuses,
      mouth, gastro-intestinal tract, etc. differ from each other. The make-up of the microbiome -
      which bacteria are found in a site - may be necessary for good health. For example, the
      microbiome of the mouth is different in people with inflammation of the gums (periodontitis),
      and the microbiome of the bowel is different in people with inflammation of the intestinal
      tract (inflammatory bowel disease).

      The purpose of this research study is to find out if the microbiome in the lungs is different
      in healthy people without asthma compared to people with asthma. This study will also find
      out if the microbiome of the lungs changes when people with asthma take a daily &quot;controller&quot;
      medication called an inhaled corticosteroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two broad specific aims of this study are: 1)To evaluate whether the microbiota of the
      bronchial airways in atopic asthmatics and atopic healthy controls differ in microbial
      diversity, richness, evenness, or composition of specific bacterial taxa. 2) To determine
      whether inhaled corticosteroid treatment alters bronchial microbial community composition in
      asthmatics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial Community Richness</measure>
    <time_frame>baseline and after 6 weeks of treatment</time_frame>
    <description>Richness is the total number of different bacterial taxa detected in the sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial Community Diversity</measure>
    <time_frame>baseline and after 6 weeks of treatment</time_frame>
    <description>The Shannon diversity index is a type of entropy measure and is a function of the distribution of the total number of organisms across all of the species. If S is the total number of species in the sample and p_i is the number of organisms in the i-th species divided by the total number of organisms, then Diversity = −Σ p_i log(p_i).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial Community Evenness</measure>
    <time_frame>baseline and after 6 weeks of treatment</time_frame>
    <description>Pielou's evenness index is a scaled measure of biodiversity and is equal to the observed Shannon diversity index divided by the maximum possible Shannon diversity index, which would occur if all of the species in the sample were equally abundant. Evenness = D/log(S), where D is the Shannon Diversity index and log(S) is the maximum diversity of the sample.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Asthma</condition>
  <condition>Atopy</condition>
  <arm_group>
    <arm_group_label>Inhaled corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone (250 mcg/puff, one puff, twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo fluticasone (one puff, twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic Non-asthmatics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone</intervention_name>
    <description>Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day</description>
    <arm_group_label>Inhaled corticosteroid</arm_group_label>
    <other_name>Flovent 250</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry Powder Inhaler: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Asthmatic:

          -  History of physician-diagnosed asthma.

          -  Methacholine PC20 &lt; 8mg/ml and/or FEV1 improvement ≥ 12% in response to 180 mcg
             albuterol.

          -  FEV1 ≥ 70% of predicted after 180 mcg albuterol.

          -  Stable asthma for ≥ 3 months prior to enrollment (no urgent care visits, no systemic
             corticosteroid treatment).

          -  Asthma Control Questionnaire 6 Score &lt; 1.5.

          -  Able to provide informed consent.

          -  Able to perform spirometry as per ATS criteria.

          -  Evidence by allergen skin test of sensitivity to an aeroallergen.

          -  Willingness, if female and able to conceive, to utilize one medically-acceptable form
             of contraception.

        Healthy Control:

          -  Evidence by allergen skin test of sensitivity to an aeroallergen.

          -  Able to provide informed consent.

          -  Able to perform spirometry as per ATS criteria.

        Exclusion Criteria:

        Asthmatic:

          -  Presence of lung disease other than asthma.

          -  Use of &gt; 10 doses of nasal corticosteroids in the previous 3 months.

          -  Presence of significant medical illness or other chronic diseases whose treatment
             could affect the clinical features measured, responses to the therapies to be given in
             this study, or risks of participating in the study.

          -  History of atrial or ventricular tachyarrhythmia.

          -  Changes suggestive of cardiac ischemia on ECG at baseline.

          -  History of upper respiratory infection, sinusitis, bronchitis, or antibiotic use in
             the previous 3 months.

          -  History of chronic sinus disease.

          -  Smoking &gt; 5 pack-years, or within the past year

          -  History of long-term controller medication use for asthma (inhaled or oral
             corticosteroid, leukotriene pathway antagonist, cromolyn, or theophylline within the
             preceding 6 months.

          -  History of bleeding disorder.

          -  Reduced creatinine clearance.

          -  Inability, in the opinion of the Study Investigator, to coordinate use of inhaler or
             otherwise comply with medication regimens.

          -  Contraindication to bronchoscopy on history or examination.

        Healthy Control:

          -  History of chronic respiratory disease including asthma.

          -  Presence of significant medical illness or other chronic diseases whose treatment
             could affect the clinical features measured, responses to the therapies to be given in
             this study, or risks of participating in the study.

          -  History of atrial or ventricular tachyarrhythmia.

          -  Changes suggestive of cardiac ischemia on ECG at baseline.

          -  History of upper respiratory infection, sinusitis, bronchitis, or antibiotic use in
             the previous 3 months.

          -  Methacholine PC20 &lt; 16 mg/ml or FEV1 improvement ≥ 12% in response to albuterol.

          -  History of chronic sinus disease

          -  Smoking &gt; 5 pack-years, or within the past year

          -  Use of &gt; 10 doses of a nasal corticosteroid preparation in the previous 3 months

          -  FEV1 or FVC &lt; 80% predicted.

          -  History of bleeding disorder.

          -  Reduced creatinine clearance.

          -  Contraindication to bronchoscopy on history or examination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lewis Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Homer Boushey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sally Wenzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Sorkness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco, Adult</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Adult</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53972</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <results_first_submitted>March 11, 2016</results_first_submitted>
  <results_first_submitted_qc>November 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2016</results_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Professor of Public Health Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Healthy controls and non-atopic asthmatics assessed only at baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Corticosteroid</title>
          <description>Fluticasone (250 mcg/puff, one puff, twice a day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo fluticasone (one puff, twice a day)</description>
        </group>
        <group group_id="P3">
          <title>Healthy Control</title>
        </group>
        <group group_id="P4">
          <title>Atopic Non-asthmatics</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atopic Asthmatics Treated With Inhaled Corticosteroid</title>
          <description>Fluticasone (250 mcg/puff, one puff, twice a day)</description>
        </group>
        <group group_id="B2">
          <title>Atopic Asthmatics Treated With Placebo</title>
          <description>Placebo fluticasone (one puff, twice a day)</description>
        </group>
        <group group_id="B3">
          <title>Atopic Non-asthmatics</title>
        </group>
        <group group_id="B4">
          <title>Healthy Control</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="26" upper_limit="40"/>
                    <measurement group_id="B2" value="37" lower_limit="25" upper_limit="40"/>
                    <measurement group_id="B3" value="28" lower_limit="25" upper_limit="42"/>
                    <measurement group_id="B4" value="28" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B5" value="30" lower_limit="25" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second</title>
          <units>percent of predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="B2" value="84" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="B3" value="98" lower_limit="89" upper_limit="108"/>
                    <measurement group_id="B4" value="100" lower_limit="94" upper_limit="107"/>
                    <measurement group_id="B5" value="96" lower_limit="86" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Eosinophils</title>
          <units>percent of cells in blood sample</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" lower_limit="1.3" upper_limit="5.7"/>
                    <measurement group_id="B2" value="3.6" lower_limit="2" upper_limit="4.8"/>
                    <measurement group_id="B3" value="2.0" lower_limit="1.4" upper_limit="2.9"/>
                    <measurement group_id="B4" value="1.4" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="2.0" lower_limit="1.2" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sputum eosinophils</title>
          <units>percent of cells in sputum sample</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.3" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="B2" value="0.7" lower_limit="0" upper_limit="1.5"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="0.45"/>
                    <measurement group_id="B4" value="0" lower_limit="0" upper_limit="0.4"/>
                    <measurement group_id="B5" value="0.2" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Microbial Community Richness</title>
        <description>Richness is the total number of different bacterial taxa detected in the sample.</description>
        <time_frame>baseline and after 6 weeks of treatment</time_frame>
        <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Atopic Asthmatics Treated With Inhaled Corticosteroids</title>
          </group>
          <group group_id="O2">
            <title>Atopic Asthmatics Treated With Placebo</title>
          </group>
          <group group_id="O3">
            <title>Atopic Non-asthmatics</title>
          </group>
          <group group_id="O4">
            <title>Healthy Control</title>
          </group>
        </group_list>
        <measure>
          <title>Microbial Community Richness</title>
          <description>Richness is the total number of different bacterial taxa detected in the sample.</description>
          <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
          <units>number of bacterial taxa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449" lower_limit="376" upper_limit="613"/>
                    <measurement group_id="O2" value="543" lower_limit="484" upper_limit="684"/>
                    <measurement group_id="O3" value="483" lower_limit="437" upper_limit="646"/>
                    <measurement group_id="O4" value="444" lower_limit="400" upper_limit="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 6 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456" lower_limit="351" upper_limit="578"/>
                    <measurement group_id="O2" value="405" lower_limit="385" upper_limit="714"/>
                    <measurement group_id="O3" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                    <measurement group_id="O4" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Microbial Community Diversity</title>
        <description>The Shannon diversity index is a type of entropy measure and is a function of the distribution of the total number of organisms across all of the species. If S is the total number of species in the sample and p_i is the number of organisms in the i-th species divided by the total number of organisms, then Diversity = −Σ p_i log(p_i).</description>
        <time_frame>baseline and after 6 weeks of treatment</time_frame>
        <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Atopic Asthmatics Treated With Inhaled Corticosteroids</title>
          </group>
          <group group_id="O2">
            <title>Atopic Asthmatics Treated With Placebo</title>
          </group>
          <group group_id="O3">
            <title>Atopic Non-asthmatics</title>
          </group>
          <group group_id="O4">
            <title>Healthy Control</title>
          </group>
        </group_list>
        <measure>
          <title>Microbial Community Diversity</title>
          <description>The Shannon diversity index is a type of entropy measure and is a function of the distribution of the total number of organisms across all of the species. If S is the total number of species in the sample and p_i is the number of organisms in the i-th species divided by the total number of organisms, then Diversity = −Σ p_i log(p_i).</description>
          <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
          <units>Shannon Diversity Index</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.9" upper_limit="5.6"/>
                    <measurement group_id="O2" value="5.7" lower_limit="5.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="5.6" lower_limit="5.2" upper_limit="6.0"/>
                    <measurement group_id="O4" value="5.3" lower_limit="5.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 6 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.6" upper_limit="5.7"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.8" upper_limit="5.7"/>
                    <measurement group_id="O3" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                    <measurement group_id="O4" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Microbial Community Evenness</title>
        <description>Pielou’s evenness index is a scaled measure of biodiversity and is equal to the observed Shannon diversity index divided by the maximum possible Shannon diversity index, which would occur if all of the species in the sample were equally abundant. Evenness = D/log(S), where D is the Shannon Diversity index and log(S) is the maximum diversity of the sample.</description>
        <time_frame>baseline and after 6 weeks of treatment</time_frame>
        <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Atopic Asthmatics Treated With Inhaled Corticosteroids</title>
          </group>
          <group group_id="O2">
            <title>Atopic Asthmatics Treated With Placebo</title>
          </group>
          <group group_id="O3">
            <title>Atopic Non-asthmatics</title>
          </group>
          <group group_id="O4">
            <title>Healthy Control</title>
          </group>
        </group_list>
        <measure>
          <title>Microbial Community Evenness</title>
          <description>Pielou’s evenness index is a scaled measure of biodiversity and is equal to the observed Shannon diversity index divided by the maximum possible Shannon diversity index, which would occur if all of the species in the sample were equally abundant. Evenness = D/log(S), where D is the Shannon Diversity index and log(S) is the maximum diversity of the sample.</description>
          <population>Only baseline samples were collected from atopic non-asthmatics and healthy controls. Data was not available for all participants due to insufficient amplification in some samples.</population>
          <units>Pielou’s evenness index</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.81" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.79" upper_limit="0.91"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.83" upper_limit="0.94"/>
                    <measurement group_id="O4" value="0.86" lower_limit="0.83" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 6 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.76" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.81" upper_limit="0.88"/>
                    <measurement group_id="O3" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                    <measurement group_id="O4" value="NA">Only baseline data was collected from atopic non-asthmatics and healthy controls</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected or assessed for healthy controls or atopic non-asthmatics</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Corticosteroid</title>
          <description>Fluticasone (250 mcg/puff, one puff, twice a day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo fluticasone (one puff, twice a day)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD 9</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Mauger</name_or_title>
      <organization>Penn State University</organization>
      <phone>717-531-7178</phone>
      <email>dtm5@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

